Given the limited efficacy of ICB in microsatellite instability-high or mismatch repair-deficient patients with CRC, targeting the NAT10-DKK2 axis, which is involved in suppressing CD8+ T cell function may expand the application of ICB in CRC. This evidence concerns the gene NAT10 and colorectal carcinoma.